Sonoma Pharmaceuticals, Inc. (SNOA) Stock Price & Analysis
Sonoma Pharmaceuticals, Inc. (SNOA) closed at USD 1.11 on Friday, October 23, 2026, down 3.48% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.15; the Oct 23, 2026 session ranged USD 1.11–1.13 on volume of 40,263 shares. Market capitalization is $5.32M, with a 52-week range of USD 0.85–4.1 (NCM). Source: Nexqual, retrieved October 24, 2026 at 12:40 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SNOA.md
Key facts (SNOA)
- Last four reported quarters (through Jun 30, 2026): revenue $21.9M, net income -$2.3M (-10.3% margin), free cash flow -$2.7M (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -71.2% vs S&P 500 +13.4%; 5Y -99.0% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SNOA)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.6M | $13.3M | $12.7M | $14.3M | $19.5M | $21.9M |
| Gross profit | $4.0M | $4.5M | $4.7M | $5.5M | $7.4M | — |
| Operating income | -$5.9M | -$4.6M | -$4.7M | -$3.7M | -$2.5M | -$1.4M |
| Net income | -$5.1M | -$5.2M | -$4.8M | -$3.5M | -$3.2M | -$2.3M |
| EPS (diluted) | -$38.40 | -$30.40 | -$10.63 | -$2.79 | -$1.89 | — |
| Free cash flow | -$4.4M | -$6.4M | -$2.4M | -$168K | -$4.1M | -$2.7M |
| Gross margin | 31.6% | 33.7% | 37.3% | 38.2% | 38.0% | — |
| Operating margin | -46.6% | -34.4% | -36.9% | -26.0% | -12.6% | -6.4% |
| Net margin | -40.3% | -38.8% | -38.0% | -24.2% | -16.3% | -10.3% |
| Revenue growth | -32.2% | +5.1% | -4.0% | +12.2% | +36.7% | — |
| Cash + short-term investments | $7.4M | $3.8M | $3.1M | $5.4M | $2.4M | — |
| Total debt | $0K | — | — | — | — | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (SNOA)
P/S 0.2x · P/B 0.8x · FCF yield -49.95% · Earnings yield -42.60%
Analysts (SNOA)
Consensus None.
Total return (dividends reinvested) (SNOA)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -71.2% | -99.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -71.4% | -60.6% |
| Volatility (annualized) | 76.7% | 111.7% |
| Max drawdown | -74.8% (Oct 2025→May 2026) | -99.1% (Nov 2021→May 2026) |
SNOA customer concentration
In the period ended Jun 30, 2026, 4 direct customers each accounted for at least 10% (18%, 18%, 10%, 0%) of revenue, per the company's 10-Q filed Aug 6, 2026. The company does not name them.
SNOA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year (ends Mar 2026) | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 12:40 UTC)
| Price | USD 1.11 |
|---|---|
| Change | ▼ 3.48% (down) |
| Previous Close | USD 1.15 |
| Open | USD 1.12 |
| Day Range | USD 1.11 – 1.13 |
| 52-Week Range | USD 0.85 – 4.1 |
| Volume | 40,263 shares |
| Market Cap | $5.32M |
| Exchange | NCM |
Technical Analysis (SNOA)
Nexqual's technical model rates SNOA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 12:40 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.79 (neutral) |
| vs SMA50 | Below (USD 1.26) |
| MACD | -0.04 (negative) |
Analyst Ratings (SNOA)
Wall Street analysts rate SNOA "None", per Nexqual as of October 24, 2026 at 12:40 UTC.
| Consensus Rating | None |
|---|
Earnings (SNOA)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.48 vs est -0.29 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.31 ▼ miss |
| 2025-06-30 | USD -0.76 vs est -0.51 ▼ miss |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financials & Fundamentals (SNOA)
| Total Revenue | $21.92M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +59.60% |
| Gross Margin | +38.90% |
| Operating Margin | -0.62% |
| Profit Margin | -10.33% |
| ROE | -42.52% |
| Debt / Equity | 0.11 |
| Current Ratio | 2.99 |
| Total Cash | $5.34M |
| Total Debt | $739,000 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$2.65M (-12.1% of revenue) |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Financial Health Score (SNOA)
Nexqual rates Sonoma Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 12:40 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $5M cash, no debt |
| Cash Flow | Weak — FCF negative: -$3M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -43%, ROA -5.4% |
Ownership (SNOA)
| Insider Ownership | +0.42% |
|---|---|
| Institutional Ownership | +2.31% |
| Shares Outstanding | 4.79M |
| Float | 4.77M |
| Short % of Float | +3.45% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
Leadership (SNOA)
Sonoma Pharmaceuticals, Inc. is led by Amy M. Trombly Esq., CEO, President & Director, per Nexqual as of October 24, 2026 at 12:40 UTC.
| CEO, President & Director | Amy M. Trombly Esq. |
|---|---|
| Chief Financial Officer | Jerome J. Dvonch |
| Senior Vice President of Regulatory, Quality & Product Development | Arturo Angel |
Major Backers & Investors (SNOA)
Notable institutional backers of Sonoma Pharmaceuticals, Inc. include Renaissance Technologies, Fidelity, McKinley Carter Wealth Services, Inc., according to Nexqual as of October 24, 2026 at 12:40 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.85% |
| Fidelity | 0.53% |
| McKinley Carter Wealth Services, Inc. | 0.23% |
| UBS Group AG | 0.16% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.56% |
| Vanguard Group | 0.39% |
Source: Nexqual, October 24, 2026 at 12:40 UTC.
From Sonoma Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-06-16)
Key Strengths & Strategy (as disclosed to the SEC)
- Food and Drug Administration, or FDA, clearances permitting the sale of products as medical devices under Section 510(k) of the Federal Food, Drug and Cosmetic Act, including wound care and dermatological indications for: and advanced tissue care with a European Conformity marking, Conformité Européenne, or CE.
- For the year ended March 31, 2025, customer B represented 21% and customer C represented 18% of net revenues. and maintain proprietary protection for product technology and know-how, to operate without infringing proprietary rights of others, and to prevent others from infringing on our proprietary rights.
- We have been in business for over 20 years, and in that time, we have developed significant scientific knowledge of how best to develop and manufacture HOCl products backed by decades of studies and data collection along with manufacturing experience.
- In Europe and the United Kingdom, we have developed products to assist in the treatment of acne.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BHC | Bausch Health Companies Inc. | USD 6.44 | ▼ 0.77% |
| HCM | HUTCHMED (China) Limited | USD 14.36 | ▲ 0.56% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 27.2 | ▼ 4.8% |
| LQDA | Liquidia Corporation | USD 42.65 | ▲ 7.46% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.47 | ▼ 2.43% |
| RGC | Regencell Bioscience Holdings L | USD 7.67 | ▼ 21.81% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 12:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt